A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Running, not enrolling · Phase 3

Conditions studied: Pterygium

In brief

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.

Key facts

Study ID
NCT05456425
Run by
Cloudbreak Therapeutics, LLC
People needed
660
Starts
2022-06-30
Expected to finish
2027-12-31
Last updated by the study team
2025-09-24

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.